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OBJECTIVES: The proportion of depressed individuals in usual
practice who develop treatment resistant depression (TRD) is not
known, in part because of varied deﬁnitions. One deﬁnition of
TRD that has gained some consensus is the failure of two anti-
depressant trials of adequate dose and duration for the same
depressive episode. The objective of this study was to operation-
alize this deﬁnition of TRD in administrative claims data and
estimate the prevalence of TRD among individuals with major
depression. METHODS: Retrospective analysis of PharMetrics
Integrated Outcomes Database of adjudicated medical and phar-
maceutical claims from multiple commercial U.S. health plans.
We identiﬁed 168,533 adults (age 18–64) with a diagnosis of
major depression (ICD-9-CM 296.20–296.39), treatment with
an antidepressant, and with continuous enrollment for one year
following the initiation of the antidepressant. TRD was identiﬁed
based on the initiation of a third antidepressant after treatment
with two antidepressants of adequate dose and duration. In
sensitivity analyses, we varied the deﬁnition of “adequate dura-
tion” and the length of gaps between antidepressants. RESULTS:
There were 12,125 individuals (7.2%) who started a third anti-
depressant after taking 2 different antidepressants for at least 42
days each, with at least one script of adequate dose, and a gap of
less than 30 days between different antidepressant treatments.
Increasing the gap between the ending of one antidepressant
treatment and the initiation of the next to 60 days or 90 days
resulted in identiﬁcation of 16,494 (9.8%) and 19,273 (11.4%)
cases of TRD, respectively. CONCLUSION: In usual medical
care, 7.2% of individuals who are diagnosed with major depres-
sion appear to develop treatment resistant depression. For this
small, but meaningful proportion of individuals with major
depression, three or more antidepressant trials appear to be
needed to sufﬁciently control symptoms.
PMH16
ASSOCIATION BETWEEN ATYPICAL ANTIPSYCHOTIC USE
ANDTREATMENT-EMERGENT DIABETES, HYPERLIPIDEMIA,
AND OBESITY
Lingle EW1, Dickson M2
1University of South Carolina, Columbia, SC, USA, 2University of
South Carolina, College of Pharmacy, Columbia, SC, USA
OBJECTIVES: To assess the relationship between newly initiated
atypical antipsychotic (AA) use and subsequent diagnoses for
the metabolic disorders (MD) of hyperlipidemia, diabetes, and
obesity. METHODS: Enrollees in the South Carolina Medicaid
program were included if they initiated AA therapy in 2003 or
2004 (index date), did not have a MD diagnosis in the 12 months
prior to the index date, used only a single AA drug for the 12
months prior to and following the index date (follow-up), and
were continuously eligible during follow-up. A comparison
group with the same inclusion criteria was selected except this
group did not have a MD during follow-up. Multivariate logistic
regression was used for analysis with each of the three MDs as
dependent variables. Independent variables included age, race,
gender, and AA used with clozapine as the comparator.
RESULTS: A total of 19,388 patients were identiﬁed (1,788 with
a MD and 17,600 without MD). The study population was
46.7% male, 52.1% white, and had an average age of 42.7 (SD
24.2). In patients diagnosed with diabetes, olanzapine
(OR = 1.59, 95% CI = 1.22–2.08, p = 0.001) and risperidone
(OR = 1.47, CI = 1.12–1.92, p = 0.005) had signiﬁcantly higher
diagnosis rates. Patients taking risperidone (OR = 1.70, 95%
CI = 1.15–2.53, p = 0.001) had a signiﬁcantly higher rate of
hyperlipidemia. Patients diagnosed with obesity had a signiﬁ-
cantly higher rate of diagnosis if they used olanzapine
(OR = 1.85, 95% CI = 1.11–3.10, p = 0.020) or risperidone
(OR = 1.92, 95% CI = 1.15–3.20, p = 0.012). CONCLUSION:
Findings of this Medicaid-based study indicate that higher rates
of diabetes, hyperlipidemia, and obesity are associated with use
of certain atypical antipsychotics. Additional research is needed
to conﬁrm and elaborate the speciﬁcs of these metabolic disor-
ders associated with atypical antipsychotic use.
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OBJECTIVES: Estimate the costs of prescription opioid analge-
sic (“RxO”) abuse in the U.S., and costs savings realized
from introducing abuse-deterrent formulations (“ADFs”).
METHODS: The costs associated with RxO abuse were grouped
into three major cost categories: health care, lost productivity,
and criminal justice. Each category has multiple underlying com-
ponents. Relying primarily on published data, we used varying
methods depending on the cost component considered. In
general, cost estimates and potential cost savings due to speciﬁc
characteristics of ADFs were obtained by either: a) multiplying
the relevant number of RxO abusers based on various national
surveys (e.g., National Household Survey on Drug Abuse, Treat-
ment Admissions Data Set, Drug Abuse Warning Network) for
prevalence estimates by the per abuser cost; or b) determining the
overall costs to the U.S. for drug abuse in general and apportion-
ing the share due to RxO abuse. RESULTS: Total costs of RxO
abuse in the U.S. in 2006 USD were approximately $10 billion.
Of these costs, $3 billion were health care costs, $5.2 billion were
lost productivity costs, and $1.8 billion were criminal justice
costs. These estimates are conservative in that some cost catego-
ries and components are not included. Sensitivity analyses found
that costs for the estimated cost categories and components could
range higher. CONCLUSION: The costs of RxO abuse in the
U.S. impose a substantial economic burden to society. Rising
trends of RxO abuse internationally suggest an escalating eco-
nomic and public health burden in coming years, and the devel-
opment and introduction of ADFs could save much money.
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OBJECTIVES: Cost evaluation of prescribing patterns for citalo-
pram and escitalopram in two outpatient settings. METHODS:
Prescribing patterns of citalopram and its enantiomer escitalo-
pram were studied separately in 2 clinical settings from January
2000 to March 2007. Setting 1 included all prescriptions from
GPs and specialists installed in the canton of Geneva. All ﬁlled
prescriptions are systematically recorded by a unique pharma-
cist’s organisation (OFAC invoice ofﬁce), which represents 92%
of all prescriptions ﬁlled in the canton Geneva (around 500,000
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